I
Immatics focuses on developing precision therapies by targeting the PRAME antigen, which is expressed across more than 50 different cancer types. The company is advancing a pipeline of targeted cell therapies and bispecific product candidates through active clinical trials. This approach aims to provide novel treatment options for patients with significant unmet medical needs in oncology.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Immatics focuses on developing precision therapies by targeting the PRAME antigen, which is expressed across more than 50 different cancer types. The company is advancing a pipeline of targeted cell therapies and bispecific product candidates through active clinical trials. This approach aims to provide novel treatment options for patients with significant unmet medical needs in oncology.